



ProstaLund receives a contract of SEK 2.4 million

ProstaLund and SLG Kalmar AB have signed a new agreement regarding disposable materials for CoreTherm® treatments.

ProstaLund and the new owner of the Specialist Medical Group in Kalmar, SLG Kalmar AB, have today signed a new agreement regarding disposable materials used in CoreTherm® treatments. The agreement extends over twelve months, with an option for extension. The order value is approximately SEK 2.4 million during the contract period.

"It is satisfying that we now have an agreement in place in Kalmar. The Kalmar clinic has always been a stronghold for us. The change of ownership of the clinic on January 1 last year meant that the care agreements that the previous owners had with Region Kalmar ended and the officials in the region failed to give the new owner a corresponding agreement, which has greatly affected the number of treatments in 2022. In August, the clinic received a new agreement containing CoreTherm® - treatments, with the region. That agreement extends over 4 years. For ProstaLund, the agreement that we have now signed means that we get continuity in terms of both orders and cash flow, which allows us to continue our pace of expansion according to plan," says CEO Johan Wennerholm in a comment.

For further information, please contact:

Johan Wennerholm, CEO
Tel. +46 (0) 730 429997
Email: johan.wennerholm@prostalund.com

About ProstaLund

ProstaLund AB is a Swedish medical technology company and a leading developer and manufacturer of innovative urological devices and treatments. The company's lead product, CoreTherm, is a patented ThermoTherapy treatment method for Benign Prostatic Hyperplasia (BPH) which can be tailored to suit the needs of each individual patient. CoreTherm is used today in hospitals and clinics in Sweden and worldwide. ProstaLund is listed on the Nasdaq First North Growth Market.

Certified Adviser:

Västra Hamnen Corporate Finance AB
Phone: +46 40 200 250
E-mail: ca@vhcorp.se



PRESS RELEASE
02 February 2023 10:05:00 CET

This information is information that ProstaLund AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-02-02 10:05 CET.

Attachments

ProstaLund receives a contract of SEK 2.4 million